Trials show new cancer vaccine could improve patient survival for some lung cancers by nearly half

A French biotechnology company said that its cancer vaccine was effective in decreasing the risk of death for people with some lung cancers by 41%.

Transcript

00:00 [Music]

00:13 We have a biomarker that allows us to select the patients who will be vaccinated.

00:18 It's a bit like the Identity Card of the military, like the blood groups.

00:21 It's called HLA-A2.

00:23 So, 45% of the population, at birth, genetically, is eligible for this vaccination.

00:28 Then, 50% of the patients who have responded to immunotherapy

00:32 will be able to enter a vaccination protocol,

00:35 which means that we are on about 7 to 10,000 patients per year in France.

00:38 If we expand to the European, American and Chinese scales,

00:42 we are on a little over 100,000 patients per year

00:45 who could receive this type of vaccination in the lung cancer.

00:49 [Music]

01:04 In 2023, we should have a breakthrough in cancer-fighting therapeutic vaccines.

01:10 Our Phase 3 results for patients with very advanced lung cancer.

01:13 We saw Moderna in December 2022 with a Phase 2.

01:16 We saw good results in preventing the tumor's receding

01:21 in lung cancer, melanoma, after surgery.

01:24 So, we are very preventive, and we combine it with other immunotherapies

01:29 to prevent patients from progressing and entering these heavy chemotherapy protocols.

01:34 [Music]